Segment Covered
The report on global metabolic disorders therapeutics market covers segments such as, disease type and
product. On the basis of disease type the global metabolic disorders therapeutics market is categorized into
diabetes, obesity, hypercholesterolemia and lysosomal storage disease. On the basis of product the global
metabolic disorders therapeutics market is categorized into metachromatic leukodystrophy, globoid
leukodystrophy, hepatic encephalopathy and others.
Make an Enquiry
https://www.infiniumglobalresearch.com/reports/enquiry/145
Geographic Coverage
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and
Rest of the World. In this section the key trends and market size for each geography is provided over the
period of 2015-2023.
The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific
includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France,
Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North
America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for
the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to
experience a growth at a CAGR of x.x% over the period of 2017-2023.
Companies Profiled:
The report provides profiles of the companies in the global metabolic disorders therapeutics market such as,
Astazeneca Plc, Novo Nordisk, Sanofi, Merck, Eli Lily, AbbVie, Actelion Pharmaceuticals, Amicus Therapeutics,
Arena Pharmaceuticals and Biocon.
Infinium Global Research